Flagship fund of Eventide Asset Management seeks outperformance by investing in companies that serve stakeholders and the global common good "We founded Eventide with the conviction that businesses ...

BOSTON, Dec. 17, 2025 /PRNewswire/ -- For the fifth year in a row, Eventide Asset Management was recognized in the 2025 Best Places to Work in Money Management awards announced by Pensions & ...

Eventide's dedicated private investment fund targets drug research for underserved patient populations. "Biotech is an area where we believe investors can profoundly address the world's greatest unmet ...

BOSTON, Sept. 30, 2025 /PRNewswire/ -- Eventide Asset Management, LLC, a Boston-based investment adviser, announces the launch of three systematic ETFs: the Eventide Large Cap Growth ETF (ESLG), ...

The MarketWatch News Department was not involved in the creation of this content. BOSTON, Nov. 12, 2025 /PRNewswire/ -- Eventide Asset Management announces filing approval for the latest of their ...

Eventide survey highlights potential opportunity for advisors to serve Christian investors' desire for values-based investing. BOSTON, Oct. 31, 2024 /PRNewswire/ -- Nearly 9-in-10 Christians (88%) who ...

Boston-based Eventide Asset Management sold 114,922 shares of Mirum Pharmaceuticals during the third quarter. Despite the sale, the overall value of the position increased by about $50.70 million from ...

Eventide Funds has confounded the investment world with its success—and its biblically based principles. Not long ago, when reporters wrote about Robin John, the cofounder of Eventide Asset Management ...

BOSTON, Aug. 22, 2024 /PRNewswire/ -- Eventide Asset Management is pleased to announce the hire of I-hung Shih, PhD as a Managing Director of Eventide Ventures and as Portfolio Manager of the Eventide ...

Joining me now, Mike Schnackenberg Head of Distribution at Eventide Asset Management. Mike, thanks so much for joining us. MIKE SCHNACKENBERG Well thanks for having me, Caroline CAROLINE WOODS Mike, ...

Financing led by Perceptive Xontogeny Venture Funds, SR One, and Eventide Asset Management, with participation by new and current healthcare investors Funds to support Phase 2b development of AP01 and ...